Journal ArticleDOI
The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)
Philip S. Helliwell,Philip S. Helliwell,Oliver FitzGerald,Jaap Fransen,Dafna D. Gladman,Gerald G Kreuger,Kristina Callis-Duffin,Neil McHugh,Philip J. Mease,Vibeke Strand,Robin Waxman,Valderílio Feijó Azevedo,Adriana Beltran Ostos,Sueli Carneiro,Alberto Cauli,Luis R Espinoza,John A. Flynn,Nada Hassan,Paul J. Healy,Eduardo Kerzberg,Yun Jong Lee,Ennio Lubrano,Antonio Marchesoni,Helena Marzo-Ortega,Giovanni Porru,Elvia G. Moreta,Peter Nash,Helena Raffayova,Roberto Ranza,Siba P. Raychaudhuri,Euthalia Roussou,Raphael Scarpa,Yeong Wook Song,Enrique R. Soriano,Paul P. Tak,Ilona Ujfalussy,Kurt de Vlam,Jessica A. Walsh +37 more
Reads0
Chats0
TLDR
Two new composite measures to assess disease activity in PsA have been developed by multiple linear regression and empirically, utilising physician-defined cut-offs for disease activity, and area under the receiver operating curves (AUC) were generally smaller.Abstract:
Objective To develop new composite disease activity indices for psoriatic arthritis (PsA). Methods Data from routine clinic visits at multiple centres were collected in a systematic manner. Data included all domains identified as important in randomised controlled trials in PsA. Decisions to change treatment were used as surrogates for high disease activity. New indices were developed by multiple linear regression (psoriatic arthritis disease activity score: PASDAS) and empirically, utilising physician-defined cut-offs for disease activity (arithmetic mean of desirability functions: AMDF). These were compared with existing composite measures: Composite Psoriatic arthritis Disease Activity Index (CPDAI), Disease Activity for PSoriatic Arthritis (DAPSA), and Disease Activity Score for rheumatoid arthritis (DAS28). Results 161/503 (32%) subjects had treatment changes. Although all measures performed well, compared with existing indices, PASDAS was better able to discriminate between high and low disease activity (area under receiver operating curves (ROC)) curve with 95% CI: PASDAS 0.773 (0.723, 0.822); AMDF 0.730 (0.680, 0.780); CPDAI 0.719 (0.668, 0.770); DAPSA 0.710 (0.654, 0.766); DAS28 0.736 (0.680, 0.792). All measures were able to discriminate between disease activity states in patients with oligoarthritis, although area under the receiver operating curves (AUC) were generally smaller. In patients with severe skin disease (psoriasis area and severity index >10) both nonparametric and AUC curve statistics were nonsignificant for all measures. Conclusions Two new composite measures to assess disease activity in PsA have been developed. Further testing in other datasets, including comparison with existing measures, is required to validate these instruments.read more
Citations
More filters
Journal ArticleDOI
The Psoriatic Arthritis Registry of Turkey: results of a multicentre registry on 1081 patients
Umut Kalyoncu,Ozun Bayindir,Mustafa Ferhat Öksüz,Atalay Dogru,Gezmiş Kimyon,Emine Figen Tarhan,Abdulsamet Erden,Sule Yavuz,Meryem Can,Gozde Yildirim Cetin,Levent Kılıç,Orhan Küçükşahin,Ahmet Omma,Cem Ozisler,Dilek Solmaz,Emine Duygu Ersözlü Bozkirli,Lütfi Akyol,Seval Pehlevan,Esen Kasapoglu Gunal,Fatos Arslan,Baris Yilmazer,Nilgün Atakan,Sibel Zehra Aydin +22 more
TL;DR: The PsA registry of Turkey had similarities with previously published registries, supporting its external validity and the finding that women had more fatigue and worse functioning as well as the high percentage of active disease state highlight the unmet need in treatment of PsA.
Journal ArticleDOI
Measuring psoriatic disease in clinical practice. An expert opinion position paper.
Ennio Lubrano,Fabrizio Cantini,Antonio Costanzo,Giampiero Girolomoni,Francesca Prignano,Ignazio Olivieri,Raffaele Scarpa,Antonio Spadaro,Fabiola Atzeni,Alessandra Narcisi,Federica Ricceri,Piercarlo Sarzi-Puttini +11 more
TL;DR: A joint dermatologist-rheumatologist roundtable discussion was convened to share evidence on the real-life use of methods for measuring psoriasis severity comprehensively and on the assessment tools more suitable for measuring disease activity and/or severity in clinical practice.
Journal ArticleDOI
A 2-year observational study on treatment targets in psoriatic arthritis patients treated with TNF inhibitors.
Maria Sole Chimenti,Paola Triggianese,Paola Conigliaro,M. Tonelli,G. Gigliucci,L. Novelli,Miriam Teoli,Roberto Perricone +7 more
TL;DR: TNFi are highly effective in achieving treatment targets in PsA patients and DAS28, CPDAI, DAPSA, and MDA show a good agreement, while female sex and MetS are associated with a lower probability to achieve remission inPsA patients.
Journal ArticleDOI
It’s not just the joints, it’s the whole thing: qualitative analysis of patients’ experience of flare in psoriatic arthritis
TL;DR: It is clear that flare in PsA is more than a swollen or tender joint count as measured in clinical practice, and a number of components of flare are identified from the patient perspective.
Journal ArticleDOI
Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study
Laura C. Coates,Dafna D. Gladman,Peter Nash,Oliver FitzGerald,A. Kavanaugh,Tore K Kvien,Laure Gossec,Vibeke Strand,Lawrence Rasouliyan,Luminita Pricop,Kevin Ding,Steffen M Jugl,Corine Gaillez +12 more
TL;DR: Secukinumab-treated patients achieving remission/LDA reported significantly greater improvements in PROs, including physical function and different dimensions of health-related quality of life and work, than patients in HDA through 2 years.
References
More filters
Journal ArticleDOI
Measurement of patient outcome in arthritis.
TL;DR: A structure for representation of patient outcome is presented, together with a method for outcome measurement and validation of the technique in rheumatoid arthritis, and these techniques appear extremely useful for evaluation of long term outcome of patients with rheumatic diseases.
Journal ArticleDOI
Severe psoriasis--oral therapy with a new retinoid.
T. Fredriksson,Ulf Pettersson +1 more
TL;DR: Ro 10--9359 proved to be an extremely potent antipsoriatic drug and a more than 90% reduction of psoriatic lesions could be seen in 10 patients out of 20 after 4-8 weeks of treatment.
Journal ArticleDOI
Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria
A.M. van Gestel,M.L.L. Prevoo,M.A. van 't Hof,M. H. Van Rijswijk,L. B. A. Van De Putte,P.L.C.M. van Riel +5 more
TL;DR: EULAR response criteria showed better construct and discriminant validity than did the ACR and the WHO/ILAR response criteria for RA and the World Health Organization and International League Against Rheumatism criteria.
Journal ArticleDOI
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
TL;DR: Etanercept offers patients with psoriatic arthritis and psoriasis a new therapeutic option for control of their disease.
Journal Article
Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index
TL;DR: Five clinical measurements provide a composite index (BASMI) and define disease status in AS, which is quick, reproducible and sensitive to change across the disease spectrum.
Related Papers (5)
Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment
European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.
Laure Gossec,Josef S Smolen,Sofia Ramiro,M. de Wit,Maurizio Cutolo,Maxime Dougados,Paul Emery,Robert Landewé,Sue Oliver,Daniel Aletaha,Neil Betteridge,Jürgen Braun,G.-R. Burmester,Juan D. Cañete,Nemanja Damjanov,Oliver FitzGerald,Emma Haglund,P S Helliwell,Tore K Kvien,Rik Lories,Thomas A. Luger,Mara Maccarone,Helena Marzo-Ortega,Dennis McGonagle,Iain B. McInnes,I. Olivieri,Karel Pavelka,Georg Schett,Joachim Sieper,F. Van den Bosch,Douglas J. Veale,Jürgen Wollenhaupt,Angela Zink,D. van der Heijde +33 more
Treatment recommendations for psoriatic arthritis
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis
Laura C. Coates,Arthur Kavanaugh,Philip J. Mease,Enrique R. Soriano,Maria Laura Acosta-Felquer,April W. Armstrong,Wilson Bautista-Molano,Wolf-Henning Boehncke,Willemina Campbell,Alberto Cauli,Luis R. Espinoza,Oliver FitzGerald,Dafna D. Gladman,Alice B. Gottlieb,Philip S. Helliwell,M. Elaine Husni,Thorvardur Jon Love,Ennio Lubrano,Neil McHugh,Peter Nash,Alexis Ogdie,Ana Maria Orbai,Andrew Parkinson,Denis O'Sullivan,Cheryl F. Rosen,Sergio Schwartzman,Evan L. Siegel,Sergio Toloza,William Tuong,Christopher T. Ritchlin +29 more